Omeros ($OMER) Stock Hub: NTAP Is Live, Europe Is Pending — Can YARTEMLEA Carry the Balance Sheet?

01 Bull, base and bear scenario framework

Bull scenario

Q2 showed sharp acceleration; subsequent quarters sustain net sales, repeat center orders and broadening use. J1289 reduces billing friction, NTAP improves inpatient economics, and YARTEMLEA becomes embedded earlier in treatment protocols. CHMP reverses the negative opinion or provides a workable European route. Novo advances zaltenibart and triggers additional value.

• U.S. franchise gains credibility.
• Cash burn falls relative to revenue.
• Remaining debt becomes manageable.
• Platform receives valuation credit.

Base scenario

The launch grows but remains uneven and center-by-center. Q2 was materially better than Q1 but does not yet establish a straight-line trajectory. Reimbursement helps gradually. Europe remains unresolved or delayed. Cash is adequate but requires discipline, and valuation remains highly sensitive to each quarterly update.

• Commercial thesis stays intact.
• Stock remains catalyst-driven.
• Limited metrics preserve a discount.
• Financing risk is reduced, not eliminated.

Bear scenario

Sales show weak sequential growth or poor demand quality, centers use YARTEMLEA mainly as late rescue, and operating cash use remains high. CHMP maintains refusal. Pediatric Ultomiris obtains a label, and Omeros’ post-repurchase liquidity becomes tight enough to require new debt, equity or asset monetization.

• Commercial expectations reset lower.
• Cash runway becomes the main story.
• Dilution risk returns.
• Pipeline receives little valuation credit.

No scenario is a price forecast. Each is a conditional operating path that should be updated as reported sales, cash, regulatory documents and competitive data become available.

What Would Falsify This Reading

This page reads Omeros as a company that has stopped being a development story and become a launch: one approved product, a reimbursement pathway opening on October 1, and a European file still unresolved. Five things would show that reading to be wrong, and each is checkable against a filing, a regulator record or a quarterly report.

• The launch curve flattens. YARTEMLEA revenue is the number the whole reading rests on. A fourth quarter or later that shows sequential growth slowing rather than accelerating, once the new technology add-on payment is live from October 1, 2026, would say that the constraint is demand or access rather than reimbursement mechanics.
• The add-on payment does not change hospital behaviour. A new technology add-on payment pays hospitals an amount above the diagnosis-related group rate. It removes a financial disincentive; it does not create a prescription. If the quarters after October show no inflection, the reimbursement argument in this page is weaker than it looks.
• Europe resolves, in either direction. The re-examination was still open in the EMA record checked on October 3, 2026, after the September 14–17 CHMP plenary passed without a YARTEMLEA outcome, and no decision date is confirmed. A positive opinion would add a second market on evidence already generated; a second negative would remove it for the foreseeable future.
• A competitor reads out. The treatment setting is narrow and the competitive readouts named in this page are dated events outside the company’s control. A rival with comparable or better data in transplant-associated thrombotic microangiopathy would change the market-share arithmetic regardless of how the launch is going.
• The capital structure has to be addressed. The 2029 convertible line and the cash position reported at June 30, 2026 define how long the company can fund a commercial build without returning to the market. A refinancing, an exchange or a raise would each set terms for the common that no operating number would offset.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

02 Q2 2026: YARTEMLEA accelerated sharply and the operating line reached breakeven

Omeros reported second-quarter 2026 results on August 12. YARTEMLEA gross revenue increased to $32.2 million from $11.1 million in Q1, while net revenue increased to $28.5 million from $9.9 million. Gross-to-net adjustments were approximately 11.5%, close to 11.0% in Q1.

R&D plus SG&A totaled approximately $27.7 million. GAAP net income included an $11.5 million non-cash gain, primarily from remeasurement of the 2029-note embedded derivative; Q1 included a much larger $73.1 million gain.

Profitability caveat. The $1.8 million non-GAAP result excludes the derivative mark but still includes approximately $6.6 million of income from discontinued OMIDRIA operations. The $4.6 million interest and other income line was also elevated primarily by a Novo reimbursement for transferred zaltenibart inventory. It is therefore not a pure measure of YARTEMLEA launch profitability.

Q2 cost of product sales was approximately $0.8 million, implying a reported gross margin of about 97.2%. The 10-Q explains that some product sold was manufactured before FDA approval and its cost had previously been expensed in R&D; initial gross margin may therefore not indicate future periods. “Operating breakeven” is accurate for the reported quarter, but it should not be treated as a normalized run rate.

Post-quarter capital allocation matters. In July, Omeros paid a $60.2 million purchase price plus $0.2 million of accrued interest, $60.170 million and $223 thousand on the 10-Q table, to repurchase $30.5 million principal of 2029 notes, $60.4 million in all. Principal fell to approximately $40.3 million, conversion shares fell from about 11.5 million to 6.5 million and $8.6 million of future interest was eliminated. The 10-Q rounds the starting figure two ways, about 11.5 million shares in the debt note and 11.4 million in the management discussion, but its conversion table is exact: $70,785 thousand of principal at 161.81 shares per $1,000 gives 11,454 thousand shares before the repurchases and 6,525 thousand after them, and the table figures are the ones used here. The transaction reduced dilution and interest, but used cash at roughly twice the principal retired. The $132 million June balance is therefore not the post-buyback cash balance.

Omeros also repurchased approximately 0.5 million common shares in Q2 for $5.7 million; first-half repurchases were approximately 0.8 million shares for $9.9 million at an average of $11.70, the same average the company reports for the second quarter and for the half. Buybacks can be accretive if the launch compounds, but they increase the cost of being wrong when regulatory and launch risks remain.

Clinical and regulatory update. The CHMP opinion, adopted on June 25, 2026 on an application filed by Omeros Ireland Limited, remains negative, and Omeros has requested re-examination, including review by an Ad Hoc Expert Group. The European expanded-access program continues. In the U.S., the permanent J-code became effective July 1, and NTAP, scheduled at the time for October 1, took effect on that date. Two investigator-sponsored YARTEMLEA studies, in hyperinflammatory ARDS and in prophylaxis for children with predictably severe TA-TMA, are expected to begin enrollment by year-end 2026. OMS527 enrollment is also targeted by year-end after additional nonclinical work; OMS805 Phase 1b is targeted for late 2027. The first peer-reviewed paper on the T-CAT antimicrobial platform was published in Science Translational Medicine on June 17, 2026.

Primary sources: the Q2 earnings release filed with the SEC and the June 2026 Form 10-Q.

03 Extended summary

The central stock-market question is no longer whether narsoplimab can receive FDA approval or whether the launch can generate an initial quarter of meaningful sales. Those points are now established. The next test is durability: repeat transplant-center utilization, gross-to-net stability, reimbursement traction after J1289 and NTAP, expense control and the first formally reported post-repurchase cash balance. Future quarterly reports should therefore be read as multi-variable launch-quality tests rather than as single EPS events.

What improved

J1289 is effective, FY2027 NTAP is approved for eligible Medicare inpatients from October 1, and the adult/adolescent Ultomiris program missed its primary endpoint. These developments reduce practical reimbursement friction and near-term adult competitive pressure.

What must be proven

Q2 produced $28.5 million in net YARTEMLEA revenue, a sharp increase from $9.9 million in Q1, but one full launch quarter still cannot establish a durable commercial curve. Repeat orders, transplant-center penetration, demand quality and gross-to-net stability now matter more than promotional language or a single sequential comparison.

What remains negative

CHMP’s refusal recommendation has not been reversed. Re-examination is a procedural second review, not an approval. Liquidity also needs a fresh measurement after a $60.2 million note-repurchase purchase price plus approximately $0.2 million of accrued interest.

The thesis in one paragraph

Omeros is a post-approval, launch-stage rare-disease company with unusually concentrated upside and unusually persistent execution risk. The constructive case rests on YARTEMLEA becoming embedded in transplant-center protocols, reimbursement infrastructure accelerating hospital adoption, the adult competitive field remaining favorable and the Novo Nordisk transaction continuing to provide validation and milestone optionality. The skeptical case rests on slow or rescue-only use, a failed EMA re-examination, a high cash cost for debt reduction, limited disclosure of commercial metrics and eventual financing pressure. The correct framing on October 3 is therefore more constructive on U.S. commercial infrastructure, but not complacent on revenue quality or liquidity.

04 What changed since the July 8 version

The previous hub correctly identified the U.S. launch, the June CHMP negative opinion and the first stage of the 2029-note repurchase. The developments since then, through October 3, 2026, are set out below in date order.

U.S. regulatory position: Approved, commercially available, with no boxed warning or REMS and a first-and-only TA-TMA label.

U.S. reimbursement position: Permanent J-code active; FY2027 NTAP in effect since October 1, 2026. Administrative infrastructure is materially better.

Commercial evidence: Q2 delivered $28.5M of net revenue and $0.1M of reported operating income. Q3 must test durability, repeat ordering and post-NTAP adoption.

European position: Negative CHMP opinion under re-examination. No European authorization and no guarantee of reversal.

05 Company overview: what Omeros is

Omeros Corporation is a Seattle-based biotechnology company built around complement biology, immunologic disease, oncology, addiction-related programs and antimicrobial research. The company is now properly described as commercial-stage because YARTEMLEA began U.S. commercial distribution in January 2026. That distinction matters. Older descriptions that still call Omeros purely clinical-stage are stale and can lead to the wrong valuation framework.

The lead commercial asset is YARTEMLEA, the brand name for narsoplimab-wuug. It is a monoclonal antibody targeting MASP-2, an enzyme in the lectin pathway of complement. The FDA label covers adults and pediatric patients aged two years and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy, generally abbreviated HSCT-TMA or TA-TMA. The product is intravenously administered and is the first FDA-approved therapy specifically indicated for this condition.

Omeros is not new to commercial products. It previously developed and commercialized OMIDRIA in ophthalmic surgery before selling the product to Rayner Surgical, and it then sold the U.S. royalties it had kept to DRI Healthcare in two steps: a first portion for $125.0 million in September 2022 and the remaining receipts for $115.5 million in February 2024, so that DRI now holds all U.S. OMIDRIA royalties for 2024 through 2031. The sale sits on the balance sheet as an OMIDRIA royalty obligation of $157.9 million at June 30, 2026, $21.5 million current and $136.4 million non-current, which is non-recourse to Omeros and is settled by passing the royalties through an escrow account. That history gives management experience with reimbursement and product economics, but YARTEMLEA is a different commercial problem. It is a high-cost biologic used in a small, medically fragile population and concentrated in transplant centers, where hospital formulary review, coding, diagnosis timing, inpatient economics and complex payer workflows can determine adoption.

The second major pillar of Omeros’ current value is the 2025 transaction with Novo Nordisk for zaltenibart, formerly OMS906. Novo acquired exclusive global development and commercialization rights to the MASP-3 inhibitor. The closing delivered $240 million in upfront cash and gave Omeros potential access to additional milestones and royalties. This transaction reduced near-term financing stress and validated part of the complement platform, but it also means zaltenibart is no longer an Omeros-controlled commercial asset. Direct operating concentration has therefore increased around YARTEMLEA.

What Omeros controls directly

YARTEMLEA commercialization, the European regulatory response, retained MASP-2 programs such as OMS1029, OMS527, oncology work including OncotoX-AML, T-CAT antimicrobial research and capital allocation.

What Omeros does not control directly

Novo Nordisk’s development pace for zaltenibart, milestone timing, eventual commercial execution, international regulatory decisions and the speed at which transplant centers change clinical practice.

06 TA-TMA, the treatment setting and the MASP-2 thesis

TA-TMA is a severe complication that can arise after hematopoietic stem cell transplantation. It is characterized by endothelial injury, microvascular thrombosis, blood-cell destruction and organ dysfunction, often involving the kidneys, gastrointestinal tract, lungs, central nervous system and other organs. Patients are already medically vulnerable because of the transplant, conditioning regimens, infection risk, graft-versus-host disease, immunosuppression and overlapping toxicities. Diagnosis can be difficult because laboratory and clinical features may be attributed to other post-transplant complications.

The commercial opportunity begins with the severity and unmet need. Before YARTEMLEA, no therapy was FDA approved specifically for TA-TMA. Centers used supportive measures, modification of transplant-related triggers and, in selected cases, off-label complement inhibitors approved for other diseases. That creates a meaningful advantage for a product with a dedicated label, but it does not create automatic standard-of-care status. Transplant physicians and pharmacy committees still evaluate data quality, timing of treatment, practical administration, safety, competing protocols and reimbursement.

Why MASP-2 is different from C5 inhibition

YARTEMLEA inhibits MASP-2 and therefore targets the lectin pathway of complement. Omeros’ mechanistic argument is that lectin-pathway activation contributes to endothelial damage in TA-TMA and can be blocked while preserving classical- and alternative-pathway functions. C5 inhibitors such as eculizumab and ravulizumab act downstream. The theoretical differentiation is relevant in a transplant population at high risk of infection, although real-world treatment decisions will depend on outcomes rather than mechanism alone.

The approved label includes weight-based dosing for patients below 50 kilograms and fixed dosing for patients at or above 50 kilograms, generally once weekly with the possibility of twice-weekly administration when improvement is inadequate. The label has no boxed warning, no REMS and no listed contraindications. It does, however, warn about serious and life-threatening infections, which must be interpreted in the context of an extremely ill patient population.

Commercial implication

Omeros does not need to reach thousands of community practices. A concentrated number of transplant centers can drive much of the addressable use. That concentration can make medical education efficient, but it also means that a relatively small number of skeptical or slow-moving institutions can materially affect the launch curve.

07 FDA evidence, label and the long road from CRL to approval

The regulatory history remains essential to understanding investor behavior. In October 2021, FDA issued a complete response letter because the agency could not determine a clear treatment effect from the submitted evidence and requested additional information. This was not a simple manufacturing repair. It went to the interpretability of the clinical case, creating a much harder and longer path.

Omeros pursued formal dispute resolution. In November 2022, FDA’s Office of New Drugs denied the request to move directly into labeling discussions but identified a potential path based on historical survival information. Omeros subsequently rebuilt the application around the pivotal study, expanded-access experience, survival analyses and the severe unmet need. FDA accepted the Class 2 resubmission in 2025 and ultimately approved YARTEMLEA on December 23, 2025.

At approval, Omeros highlighted complete-response rates of 61% in the pivotal trial and 68% among evaluable patients in the expanded-access program, along with 100-day survival from TA-TMA diagnosis of 73% and 74%, respectively. The FDA prescribing information gives the pivotal-study figure as 73.4%, with a 95% confidence interval of 52.2% to 86.4%, while the 2022 Journal of Clinical Oncology publication discussed below reports 68% across its full analysis set; the two numbers come from different documents and analyses, and each is attributed to its own source here (FDA label). The evidence package was necessarily different from a large conventional randomized Phase III program. That difference explains both outcomes seen in 2026: FDA accepted the totality of evidence for a first-and-only U.S. approval, while CHMP later judged the European evidence insufficient.

The published evidence behind the label

The registrational dataset is small, and it is public. The pivotal study, NCT02222545, was single-arm and open-label, and its results appeared in the Journal of Clinical Oncology in 2022: in a full analysis set of 28 adults the response rate was 61%, organ function improved in 74% of patients, 100-day survival from TA-TMA diagnosis was 68% across the full analysis set and 94% among responders, and median overall survival was 274 days. Twenty-eight patients is a thin base for an approval, and the missing control arm is the structural limit worth keeping in mind: without a randomised comparator a study cannot separate the effect of the drug from the natural course of a condition whose outcomes vary widely from patient to patient. Khaled et al., J Clin Oncol 2022.

The work published since was built to address that gap, and it should be read for what it is: externally controlled and real-world evidence, not a second randomised trial. A comparative analysis in Blood Advances set narsoplimab-treated patients aged sixteen and over against a matched control group with high-risk TA-TMA drawn from the Kyoto Stem Cell Transplantation Group registry. The hazard ratio for mortality was 0.25, with a 95% confidence interval of 0.19 to 0.34, for the 28 patients of the single-arm study against 111 registry patients; 0.38, interval 0.28 to 0.51, for the 49 high-risk patients treated in the expanded-access programme against 121 registry patients; and 0.28, interval 0.22 to 0.37, for the two narsoplimab cohorts combined, 77 patients in all. Each comparison carried a p value below 0.0001. An external control is a stronger argument than no comparator at all and a weaker one than randomisation, because matching can only adjust for the variables a registry happens to record. Matsui et al., Blood Advances 2026.

The expanded-access programme itself was reported in the American Journal of Hematology and covers 136 patients treated between October 2017 and October 2023. Among children who received an allogeneic transplant and had high-risk TA-TMA, one-year overall survival was 75.0% when narsoplimab was given as first-line therapy, in 12 patients, and 56.2% from second line onwards, in 25 patients, 20 of whom were refractory to eculizumab. Among adults in the same situation it was 58.0% in first line, in 49 patients, and 40.5% from second line, in 16 patients. The authors reported no concerning safety signals. A separate Italian series in Bone Marrow Transplantation described 20 compassionate-use patients, 13 adults and 7 children, 19 of them high risk: 13 responded, 65% of the group, 100-day survival was 70% overall and 100% among responders, and there was no increase in infectious complications. The denominators matter as much as the percentages here. A figure of 75.0% describes twelve children, and none of these cohorts was treated inside a controlled protocol. Schoettler et al., Am J Hematol 2025; Castelli et al., Bone Marrow Transplant 2024.

The published record is therefore consistent in direction and thin in volume, which is the same tension that produced two opposite regulatory verdicts on one package. It also sets the bar for the commercial phase. Evidence of this size tends to be re-argued by payers and by prescribing centres long after a filing closes, and what settles it is accumulated clinical experience rather than the original submission.

The approval removed the largest U.S. binary risk but did not erase the evidence debate. Payers, physicians and other regulators can interpret small uncontrolled or externally controlled rare-disease datasets differently. This is why real-world adoption now carries significance beyond revenue: strong clinical experience could reinforce confidence in the label, while slow or rescue-only use could keep skepticism alive.

08 U.S. commercial launch: what Q2 proved and what must persist

Q2 evidence: gross YARTEMLEA revenue was $32.2 million and net revenue $28.5 million, versus $11.1 million and $9.9 million in Q1. Reported operating income was $0.1 million. The key follow-up is persistence across transplant centers after launch inventory and early adopters.

Omeros began commercial distribution and sales in January 2026. For the three months ended March 31, it reported $11.1 million in gross YARTEMLEA sales and $9.9 million in net sales after wholesaler distribution fees and chargebacks. That was a meaningful start for a newly launched rare-disease drug, but the first quarter included launch inventory dynamics and only a short period of commercial experience. It should be treated as a baseline, not a fully formed run rate.

Management described early adoption across transplant centers, expanding formulary access, favorable reimbursement support and growing physician experience. Those statements are encouraging, but the next stage requires operating metrics. The market will look for signs that early orders were driven by underlying patient demand rather than initial channel stocking, that centers are reordering, and that use is broadening beyond isolated rescue cases.

The most informative post-Q2 questions

• Net sales trajectory: Can Q3 sustain or exceed the $28.5 million Q2 baseline after adjusting for channel timing?
• Repeat orders: Are early centers ordering again, which would suggest a continuing patient flow and institutional comfort?
• Center penetration: Is use expanding across additional adult and pediatric transplant programs?
• Treatment timing: Is YARTEMLEA used earlier after diagnosis, or mainly after off-label therapies and severe deterioration?
• Gross-to-net: Are discounts, chargebacks, free-drug programs and payer arrangements tracking near expectations?
• Inventory quality: Does distributor inventory remain aligned with end demand?
• Medical access: Are formulary approvals and reimbursement authorizations accelerating after J1289 became effective?

Rare hospital-based launches are frequently uneven. Q2’s $28.5 million net-revenue result was a strong sequential increase, but it still deserves scrutiny because Omeros records sales on delivery to wholesalers rather than at patient administration. The qualitative details around repeat orders, centers, dosing and reimbursement may therefore matter as much as subsequent reported top lines.

Why the reimbursement news can matter operationally

The J-code and NTAP solve different problems. J1289 gives providers and payers a permanent product-specific billing identifier. NTAP can provide additional inpatient payment for qualifying Medicare cases. Together they reduce administrative and economic friction, but neither compels a physician to prescribe or a hospital to adopt. Commercial execution remains the bridge between policy support and revenue. Omeros estimates that approximately 30% of U.S. allogeneic transplant patients are Medicare beneficiaries, giving the policy a meaningful—but still limited and eligibility-dependent—commercial reach.

09 Reimbursement architecture: J1289 and the final NTAP decision

Permanent HCPCS J-code J1289

CMS assigned YARTEMLEA a permanent, product-specific Healthcare Common Procedure Coding System J-code, J1289, effective July 1, 2026. A permanent code can simplify claims, reduce ambiguity in billing and give government and commercial payers a consistent product identifier. For a biologic administered through specialized centers, this is not a cosmetic milestone. It can shorten the path from treatment decision to claim submission and reimbursement.

FY2027 New Technology Add-On Payment

In the FY2027 Inpatient Prospective Payment System final rule displayed on July 31, CMS determined that YARTEMLEA met the criteria for NTAP approval. Omeros formally announced the decision on August 3. Eligible cases will be identified through ICD-10-PCS codes XW03357 and XW04357, and CMS calculated a maximum add-on payment of $287,079 per eligible Medicare inpatient case for FY2027.

The maximum should be explained precisely. CMS does not automatically pay that amount for every administration. The payment is limited to the lesser of 65% of the average cost of the technology or 65% of the amount by which the case cost exceeds the standard MS-DRG payment. CMS used an applicant-estimated average of 12 vials per inpatient stay at a wholesale acquisition cost of $36,805 per vial, or $441,660, to establish the maximum.

FY2027 began on October 1, 2026, and the add-on payment has applied to qualifying cases since then. The practical relevance is that qualifying hospitals can receive additional payment during the period when the standard inpatient payment system has not yet fully absorbed the cost of a new technology. Omeros stated that approximately 30% of patients undergoing allogeneic transplantation in the United States are Medicare beneficiaries. That company estimate points to a meaningful access segment, but it should not be read as a forecast of treated patients or product revenue.

The payment mechanics are also important for valuation analysis: NTAP payments are made to eligible hospitals and do not change the amount Omeros receives for YARTEMLEA. The potential benefit is therefore indirect. Better hospital economics may reduce delays, budget objections or reluctance to use a high-cost inpatient therapy, but the policy does not raise Omeros’ per-patient selling price and does not guarantee utilization.

What the August 3 announcement adds

The underlying CMS decision was already contained in the July 31 final rule. The new Omeros communication makes the commercial framing explicit: implementation begins October 1, the maximum is $287,079 for an eligible Medicare inpatient, payments go to hospitals rather than Omeros, and management expects the support to help treatment decisions follow clinical need rather than hospital reimbursement constraints. That final point is management’s expectation and still requires confirmation through launch data.

U.S. access infrastructure — progression during 2026

This visual represents milestone completion, not probability of commercial success. Realized reimbursement and revenue depend on patient eligibility, hospital coding, treatment setting and payer rules.

The strongest interpretation is that Omeros has built a much cleaner reimbursement platform than it had at launch. The cautious interpretation is that reimbursement support can facilitate demand but cannot manufacture it. The next evidence must come from actual center behavior and net sales.

10 Europe: re-examination is active, but the CHMP opinion remains negative

CHMP adopted a negative opinion for Yartemlea on June 25, and EMA published the refusal recommendation on June 26. On July 15, EMA updated the product page to confirm that Omeros requested re-examination. Once the company’s detailed grounds are received and assessed, CHMP will conduct a new review and issue a final recommendation.

The procedural update preserves a European pathway, but it must not be described as a reversal. Yartemlea is not approved in the European Union. The June opinion remains negative unless the re-examination produces a different conclusion. The process centers on reassessing the original opinion and the company’s detailed grounds; it should not be confused with starting an entirely new clinical development program during the review window.

Why CHMP recommended refusal

EMA said the application did not provide sufficient evidence of effectiveness. The agency emphasized that the main study lacked a placebo or active comparator, that patients received other therapies, and that aspects of study conduct, endpoint assessment and dose selection complicated interpretation. It also considered the external survival comparison unreliable for confirming effect and found the pediatric evidence insufficient to establish dose and benefit-risk.

Omeros’ counterargument

Omeros argues that the pivotal study, expanded-access experience, external-registry survival analyses and compassionate-use data support a clinically meaningful effect in a rare and lethal condition. Management has also stressed that the overall evidence package supported FDA’s U.S. approval. The company intends to seek review by an Ad Hoc Expert Group composed of external scientific and clinical experts.

The disagreement is therefore substantive, not administrative. FDA accepted a totality-of-evidence approach; CHMP judged the package insufficient. A favorable re-examination would restore a major geographic expansion opportunity and strengthen global validation. An unchanged negative opinion would likely keep the commercial thesis primarily U.S.-centered and could require a longer European strategy involving new evidence, a revised filing path or both.

Regulatory status discipline

“Re-examination requested” is a factual positive because it keeps the process alive. “European approval back on track” would be an unsupported conclusion. Until CHMP issues its post-re-examination recommendation, Europe remains a high-risk optionality layer rather than a base-case revenue assumption.

11 Competitive landscape: the Ultomiris readout helps, but does not end the race

The most important competitive development arrived on July 27. AstraZeneca reported that the randomized Phase III ALXN1210-TMA-313 study of Ultomiris, or ravulizumab, did not achieve statistical significance on its primary endpoint of event-free survival through 26 weeks versus placebo in adults and adolescents aged 12 years or older with HSCT-TMA. AstraZeneca defines the endpoint as the time from randomisation until clinical worsening or death; the trial enrolled 146 patients.

This is strategically favorable for Omeros. Ultomiris is an established complement franchise with a large commercial organization and an adult randomized dataset. Failure on the primary endpoint reduces the probability that AstraZeneca can quickly obtain a clean broad adult/adolescent label that would challenge YARTEMLEA’s first-and-only position. It also illustrates how difficult it is to demonstrate efficacy in this complex post-transplant condition, which can indirectly support the argument that FDA’s willingness to use a rare-disease totality-of-evidence framework was consequential.

However, the competitive risk has not disappeared. AstraZeneca said the study showed a trend toward benefit and that discussions with health authorities are continuing. More importantly, for the separate open-label pediatric Phase III programme, which enrolled 41 patients, AstraZeneca’s July 27, 2026 announcement gives overall survival of 87.2% at 26 weeks and 73.4% at 52 weeks, and the company is advancing pediatric regulatory filings supported by those data and an external-control study. Without a concurrent control arm, those rates describe the treated group rather than an effect measured against a comparator. AstraZeneca announcement →

The correct competitive conclusion is narrower than the bullish social-media version. Omeros’ adult U.S. position improved. It did not receive a permanent monopoly. What stays open from here is pediatric regulatory activity, off-label practice and any new mechanism entering TA-TMA development.

12 Market opportunity: large enough to matter, difficult to model

The addressable market cannot be estimated reliably by taking the total number of allogeneic transplants, multiplying it by the highest published TA-TMA incidence and applying list price. Every step introduces uncertainty. Diagnostic criteria vary, patients may be recognized at different stages, some cases may not be treated, duration can vary, dose intensity can change, and reimbursement differs between inpatient and outpatient settings.

Omeros has cited approximately 30,000 allogeneic transplants a year across the United States and Europe. That number is the company’s own estimate and not a registry count. The nearest published registry anchor is the EBMT activity survey, which recorded 21,023 allogeneic transplants in 2024 across 688 centres in 53 countries, a catchment covering Europe and affiliated countries but not the United States. On top of whichever transplant count is used sits literature showing that TA-TMA may develop in a meaningful proportion of recipients. The theoretical pool is therefore commercially relevant for a small biotechnology company. The actual treated market will depend on how many patients meet high-risk criteria, how early centers diagnose them, whether physicians use YARTEMLEA before or after off-label C5 inhibition, and how long therapy continues.

CMS’ final-rule discussion used an applicant estimate of 12 vials per inpatient stay and a wholesale acquisition cost of $36,805 per vial, corresponding to $441,660 in estimated drug cost for that modeled stay. This is not the same as net revenue per patient. Gross-to-net deductions, free drug, payer mix, vial utilization, treatment across settings and duration all matter. It should therefore be used to understand hospital economics and NTAP calculation, not to produce a simplistic revenue forecast.

Two adoption patterns with very different economics

Early protocol adoption

Centers diagnose promptly and use YARTEMLEA soon after high-risk TA-TMA recognition. This would support more predictable patient flow, broader use and potentially stronger outcomes.

Late rescue use

Centers reserve YARTEMLEA for patients who deteriorate or fail off-label approaches. The drug may still generate meaningful revenue, but the treated pool and commercial velocity could be smaller.

Subsequent quarters will reveal which pattern is becoming durable. Center-level repeat use, treatment timing and formulary inclusion are more useful than theoretical prevalence alone.

13 Financial position: Q2 cash generation versus the post-repurchase reality

Q2 replaces the old baseline. Cash and short-term investments were $132.0 million at June 30 and operating cash flow was positive $4.1 million. That balance precedes the July note repurchases, whose purchase price was $60.2 million plus approximately $0.2 million of accrued interest, so it cannot be used as current cash without adjustment.

At March 31, 2026, Omeros reported $135.3 million in cash and short-term investments. Q1 operating expenses were $27.3 million, down from $35.0 million in the prior-year period, primarily because OMS906-related R&D activity moved to Novo Nordisk. The company reported GAAP net income of $56.1 million, or $0.78 per basic share, but that figure included a $73.1 million non-cash gain from mark-to-market accounting on embedded derivatives associated with the 2029 notes. Excluding that item, non-GAAP adjusted net loss was $17.1 million, or $0.24 per share.

The accounting distinction is important. One quarter of reported operating income does not establish normalized profitability. Omeros is funding a launch, commercial infrastructure and a retained pipeline while collecting initial product revenue, and Q2 benefited from unusually low reported product cost on pre-approval inventory. The measures that describe the underlying business are recurring product gross profit, operating cash flow, working capital and ending liquidity. The derivative-driven GAAP headline describes something else, and the two should not be read as the same statement.

Q1 also included the repurchase of 354,471 common shares at an average price of $11.70 for $4.152 million; the $11.70 average is the company’s own figure and it holds for the quarter and for the half alike. That decision, combined with the later convertible-note repurchases, shows management actively using capital to reduce securities overhang. Whether that allocation proves attractive depends on the launch trajectory and how much liquidity remains after the July note repurchases and subsequent operations.

Management previously expressed a target of positive cash flow in 2027. That remains an operating objective, not an assured outcome. Q2 provided the first meaningful test: Omeros reached approximately operating breakeven and generated $4.1 million of company-wide operating cash flow. One positive quarter does not establish a self-funding launch; durability will require continued YARTEMLEA growth, expense discipline and careful management of the cash used for the July note repurchases.

For the six months ended June 30, operating cash use was $10.4 million. In the 10-Q, management said existing cash and investments together with expected YARTEMLEA sales should fund operations for at least 12 months from issuance. That is management’s forecast, not a guarantee: it depends materially on the pace and quality of launch revenue.

14 Capital structure: the 2029-note reset is complete, but it was expensive

Completed July transaction: Omeros repurchased $30.5 million principal of 2029 notes for a $60.2 million purchase price plus approximately $0.2 million of accrued interest. Remaining principal is about $40.3 million; potential conversion shares fell to 6.5 million and future interest fell by $8.6 million.

At March 31, Omeros had $70.8 million aggregate principal amount of 9.50% Convertible Senior Notes due 2029. The company then executed two privately negotiated repurchase rounds with certain holders.

• Omeros retired $16.0 million principal, settled on July 6, for $31.259 million plus $89 thousand of accrued interest on the 10-Q table; the Form 8-K of July 6 describes the payment as about $31.3 million inclusive of accrued and unpaid interest.
• On July 20, it completed the repurchase of approximately $14.5 million additional principal for $28.911 million plus $134 thousand of accrued interest on the 10-Q table, which the Form 8-K of July 20 rounds to about $29.0 million inclusive of accrued and unpaid interest.
• Total principal retired was $30.5 million, leaving approximately $40.3 million principal outstanding.
• Total purchase price across the completed transactions was $60.170 million, plus $223 thousand of accrued interest: about $60.2 million and $0.2 million, $60.4 million of cash.

What the Q2 filing shows about the notes that remain

The remaining 9.50% notes convert at about $6.18 a share, 161.81 shares per $1,000 of principal. From June 20, 2027 Omeros may redeem them, subject to the conditions set in the indenture, and a holder who converts before June 1, 2029 receives an interest make-whole payment. At June 30, 2026 the 10-Q carried the 2029 notes at $42.0 million and the embedded derivative linked to them at $55.2 million, and it recorded the $31.3 million owed for the first July tranche as a current liability. The second-quarter income statement includes a $1.9 million loss on extinguishment and $7.6 million of interest expense. Form 10-Q →

The Form 8-K of July 6 adds that the company “may seek to replace some or all of the cash used to repurchase the Notes with unsecured or limited-collateral debt financing(s)”. No such financing had been announced as of October 3, 2026. Two older obligations are already gone: the $17.1 million of convertible notes due 2026 were repaid at maturity on February 17, 2026, and the term loan was repaid on November 25, 2025. Form 8-K of July 6 →

Merlintrader inference, not a reported figure. The embedded derivative is measured at fair value, and its value moves with the share price, which closed at $9.51 on June 30, 2026 and at $19.04 on September 30, 2026 on Nasdaq’s data, roughly twice as high. That makes a large non-cash derivative loss in the third-quarter GAAP result plausible, the mirror image of the gains booked in the first two quarters of 2026; the actual amount depends on the valuation inputs the company uses and will be known only from the third-quarter filing.

2029 convertible-note principal outstanding

Bars show principal outstanding, not cash spent. The completed transactions used a purchase price of approximately $60.2M plus about $0.2M of accrued interest to retire $30.5M principal because the prices were linked to stock-price averaging mechanisms.

The benefit is straightforward: lower convertible principal reduces future interest burden, maturity risk and potential equity-linked overhang. The cost is equally clear: Omeros used approximately $60.2 million plus $0.2 million of accrued interest after quarter-end to retire $30.5 million principal. Cash and short-term investments were $132.0 million at June 30, but Omeros has not reported a formal post-repurchase cash balance. A mechanical subtraction would ignore operating receipts, spending and other post-quarter movements and should not be presented as actual current liquidity.

The second quarter is still the last reported quarter as of October 3, 2026. June cash predates the July note repurchases, and a current liquidity reading needs the third-quarter cash flows, any new debt transaction and commercial collections, none of which has been reported yet.

Remaining dilution and capital-allocation tools

At June 30, Omeros had 16.2 million employee and director stock options outstanding, of which 3.9 million were unvested; both figures are the company’s, and the 12.3 million already vested is a Merlintrader calculation on the two. On July 22, the board granted approximately 3.1 million additional annual options; the Forms 4 filed for three officers, covering 1.21 million of them, show an exercise price of $9.84 and expiry in 2036; these later grants should be monitored separately because subsequent exercises, expirations or cancellations can change the count. A further step followed on August 13, when Omeros filed a Form S-8 registering 10,406,236 additional shares under the Amended and Restated Omnibus Incentive Compensation Plan, the version shareholders approved on June 18, 2026 with 19,116,509 votes in favour and 12,184,390 against. Registering shares is not issuing them, but it sets the ceiling of what equity compensation can eventually absorb, and that ceiling is equal to about 14.4% of the shares outstanding on the August 7 cover of the Q2 Form 10-Q, a Merlintrader calculation on the two filed figures. The company also had its full $150 million at-the-market equity facility available after selling no ATM shares in the first half, while approximately $90.1 million remained under the common-share repurchase authorization at August 12. An authorization is capacity, not a commitment, and option counts do not equal immediate dilution. Options are already turning into shares, though: exercises brought in $11.0 million in the first half of 2026.

Why the debt transaction is not automatically bullish or bearish

Retiring equity-linked debt can be shareholder-friendly when a company has excess liquidity and a strong revenue trajectory. It can be risky when cash is scarce or the launch is uncertain. The correct judgment must incorporate the reported Q2 improvement, the still-unknown post-July cash balance and any replacement financing—not principal reduction alone.

15 Novo Nordisk and zaltenibart: validation, cash and outsourced execution

In October 2025, Novo Nordisk and Omeros announced an asset purchase and license agreement covering zaltenibart, formerly OMS906, a clinical-stage MASP-3 inhibitor designed to target the alternative complement pathway. Novo obtained exclusive global development and commercialization rights. The agreement was signed on October 10, 2025 and announced on October 15; the transaction closed on November 25, 2025, when Novo paid $240 million.

Beyond the $240 million paid at closing, the agreement provides for up to $100 million of near-term milestones; development and regulatory-approval milestones of up to $510 million, a figure that includes the near-term $100 million; and sales-based milestones of up to $1.3 billion. That puts total potential milestones at about $1.81 billion and the headline value at roughly $2.05 billion to $2.1 billion once the upfront payment is added, Merlintrader calculations on the disclosed tiers. Royalties on net sales are tiered from the high single digits to the high teens. The headline value should never be treated as guaranteed cash. Milestones depend on development, regulatory and commercial events, while royalties require an approved and successfully marketed product.

Novo intends to run a global Phase 3 trial in paroxysmal nocturnal hemoglobinuria, and Omeros’ second-quarter release describes the program as on track toward Phase 3 initiation; no Novo-sponsored Phase 3 trial of zaltenibart was registered on ClinicalTrials.gov when checked on October 3, 2026. Omeros kept its MASP-3 small-molecule programs and certain “grandfathered” MASP-3 antibodies outside the transaction, as its fourth-quarter 2025 results release explains.

The strategic benefit is substantial. Novo’s decision validated the scientific and commercial relevance of Omeros’ complement platform and gave Omeros non-dilutive capital before the YARTEMLEA launch. It also transferred the cost and risk of zaltenibart’s global development to a far larger company.

The trade-off is concentration and control. Omeros no longer controls zaltenibart’s timelines or prioritization, and the majority of future economics would accrue to Novo. Omeros investors must follow Novo pipeline disclosures for indication selection, clinical progress and milestone-triggering events. Until those events occur, zaltenibart is optionality rather than an operating revenue base.

Confirmed value already received

Upfront cash at closing, reduced near-term financing pressure, external platform validation and removal of direct zaltenibart development spending.

Conditional future value

Near-term milestones not yet received, development and commercial milestones, regulatory success, royalties and the pace of Novo’s program.

16 Pipeline beyond YARTEMLEA

The retained pipeline gives Omeros several potential value-creation paths, but it also creates a capital-allocation test. The company must avoid allowing early programs to consume the liquidity needed to establish YARTEMLEA.

The best capital-allocation outcome would be a focused model: YARTEMLEA receives the commercial resources needed to build a franchise, high-value retained programs advance through disciplined gates, external grants or partners absorb part of development cost, and Novo milestones add non-dilutive funding. The weak outcome would be broad spending across multiple early projects before the launch demonstrates self-sustaining economics.

17 Management, execution and governance

Gregory A. Demopulos, M.D., founded Omeros and has served as chairman and chief executive officer since 1994. His long tenure is inseparable from the company’s identity. Supporters see scientific depth, persistence and an ability to preserve strategic control through severe setbacks. The company’s survival after the 2021 CRL, ultimate FDA approval and the Novo transaction provide evidence for that view.

Skeptics focus on the other side of the same history: repeated delays, financing stress, complex capital structures, volatile communication cycles and an unusually long founder-led governance model. Approval improved management credibility, but the commercial phase demands a different skill set. Running market access, hospital accounts, inventory, pharmacovigilance and cost discipline is not the same as defending a regulatory thesis.

The July note repurchases sharpen the governance test. Management spent a $60.2 million purchase price plus approximately $0.2 million of accrued interest to retire $30.5 million principal of equity-linked debt. Q2 launch revenue and operating cash flow were stronger than the pre-report baseline, which improves the rationale for reducing dilution and interest. The decision still consumes substantial flexibility at an early commercial stage, so its quality will ultimately be judged by sustained YARTEMLEA demand, expense control and the first reported post-repurchase liquidity figure.

Insider transactions, board changes and ownership since July

The Forms 4 filed since the second quarter show option grants first and option exercises followed by sales afterwards. On July 22, 2026 the board granted options at an exercise price of $9.84, expiring in 2036: 1,000,000 to chairman and chief executive Gregory Demopulos and 105,000 each to Borges, vice president of finance and chief accounting officer, and Cancelmo, general counsel. Forms 4 on EDGAR →

Between August 13 and September 23, four insiders exercised options and sold the shares. Borges sold 5,000 at $16.95 on August 13, 10,906 at about $18.95 to $19.10 on August 21 and 24, and 20,000 at $20.95 on September 22 and 23, under a Rule 10b5-1 plan adopted on February 10, 2026. Director Cable sold 15,000 at $18.45 on August 20, after 7,500 at $11.61 on May 22 under a 10b5-1 plan. Director Hanish sold 15,000 at $18.53 to $19.02 on August 26 and 27, and Cancelmo sold 50,000 at about $18.54 to $18.65 on August 28 and 31. Together that is about 115,906 shares and roughly $2.2 million, a Merlintrader calculation on the filed prices; the chief executive reported no sales. As a reading rather than a fact: exercise-and-sell transactions on long-dated options, those by Borges under a pre-arranged plan, say less about management’s view than an open-market purchase would, and the amounts are small against 72.39 million shares outstanding. Across the company, option exercises brought in $11.0 million in the first half of 2026.

Joseph Schocken became a director effective August 12, 2026, taking the board to nine; his Form 3 of August 18 reports 528,082 shares, and a Form 4 filed the same day an option over 30,000 shares at $13.71. On ownership, the most recent filings name BlackRock with 5,961,792 shares, 8.2% of the class at June 30 (Schedule 13G/A filed July 29), and Ingalls & Snyder with 3,466,268 shares, 4.8%, at December 31, 2025 (Schedule 13G/A filed April 23, 2026); Vanguard reported 0% on its Schedule 13G/A of March 27, 2026, after an internal disaggregation of its reporting entities. Directors and officers held about 3.6% of the shares outstanding as of April 17, 2026 (a Merlintrader calculation on the proxy statement’s figures), or 10.5% including options as the proxy states. Short interest was 12,491,576 shares at the September 15, 2026 settlement date, about 17.3% of shares outstanding (a Merlintrader calculation) and 9.3 days to cover on Nasdaq’s figures, down from 18,103,605 at June 15. Schedule 13G filings → Nasdaq short interest →

Execution scorecard for the next two quarters

• Provide enough commercial detail to distinguish genuine patient demand from channel effects.
• Show that J-code and NTAP milestones translate into practical center access.
• Control SG&A and R&D while protecting launch quality.
• Explain post-repurchase cash runway without relying on conditional milestone headlines.
• Keep the EMA re-examination factual and avoid implying that a reversal is assured.
• Prioritize retained programs according to evidence and capital efficiency.

18 Catalyst and milestone calendar

Updated milestones: NTAP in effect since October 1, 2026; CHMP re-examination and AHEG review, with the next plenary on October 12–15, 2026 and no outcome date published; two YARTEMLEA investigator-sponsored studies expected to start enrollment by year-end; OMS527 inpatient study enrollment targeted by year-end; OMS805 Phase 1b targeted for late 2027.

The market’s hierarchy is clear. Q3 revenue durability and the first formal post-repurchase liquidity figure come first. EMA re-examination is the largest regulatory swing factor. NTAP implementation is a commercial enabler whose value must appear gradually in center behavior. Novo and pipeline updates are meaningful but secondary until they create cash or advanced clinical evidence.

19 Red flags and thesis-breakers

Commercial risk

First-and-only status does not guarantee rapid protocol adoption. Diagnosis can be inconsistent, formulary review can be slow, and physicians may initially reserve YARTEMLEA for the sickest patients or after off-label therapies fail.

Evidence and regulatory risk

The FDA approval is definitive in the United States, but CHMP’s refusal demonstrates that other regulators may not accept the same evidence package. Re-examination can maintain the negative outcome.

Liquidity and capital-allocation risk

The June 30 cash balance is stale after the July note repurchases, whose purchase price was approximately $60.2 million plus $0.2 million of accrued interest. Debt reduction is helpful only if sufficient runway remains to support the launch.

Competitive risk

The adult/adolescent Ultomiris miss is favorable, but pediatric filings continue, regulators may interpret the adult trend differently, and other complement or endothelial-targeted approaches can emerge.

Disclosure risk

A rare-disease launch can be difficult to evaluate when management provides only broad qualitative statements. Lack of center, repeat-order or demand-quality detail may keep the market skeptical even when revenue grows.

Concentration risk

Omeros transferred zaltenibart control to Novo and has no other late-stage wholly controlled commercial asset. Direct value creation is heavily dependent on YARTEMLEA execution.

20 Evergreen monitoring checklist

A disciplined Omeros watchlist should track operating evidence rather than price narratives. The following variables can be updated every quarter without rebuilding the thesis from scratch.

21 Merlintrader bottom line

October 3 bottom line: Q2 delivered the first hard evidence that YARTEMLEA can support the operating base. The open question moved from launch validation to durability and capital efficiency, because the July debt repurchase materially reduces both dilution and cash.

Omeros is in a stronger U.S. strategic position on October 3 than it was on July 8. The J-code is active, NTAP has been in effect for eligible Medicare inpatients since October 1, and the most visible adult/adolescent competitor failed its pivotal endpoint. These are not minor headlines. They improve the practical environment in which YARTEMLEA must build a market.

They do not complete the thesis. NTAP is a hospital reimbursement support mechanism, not an extra payment to Omeros and not proof of demand. Q2 net revenue of $28.5 million and positive operating cash flow materially strengthen the commercial evidence, but one full launch quarter does not prove a durable curve. Europe remains under a negative opinion despite the re-examination request, and the September CHMP plenary passed without an outcome. The company also used a $60.2 million purchase price plus approximately $0.2 million of accrued interest to retire $30.5 million principal of its 2029 converts, making the first formal post-repurchase cash disclosure a critical next data point. The pediatric competitive field remains active.

The most accurate current description is therefore: U.S. launch infrastructure has de-risked faster than commercial evidence has matured. The next re-rating, positive or negative, should be driven less by regulatory storytelling and more by sales quality, repeat center behavior, liquidity and management discipline. A successful Omeros outcome requires YARTEMLEA to become a repeatable transplant-center franchise before cash flexibility narrows. A weaker outcome would leave the company with an approved product, a valid mechanism and improved reimbursement, but insufficient adoption to support the operating structure.

For readers following $OMER, the Q2 report is now the new operating baseline, not the next checkpoint. The questions have moved forward: can $28.5 million of quarterly net revenue persist or grow, are transplant centers reordering, does reimbursement convert into broader access, what is the formal post-repurchase cash balance, and can management fund the launch without rebuilding the dilution overhang it paid to reduce?

22 Related Merlintrader reading